About
Copy Link
Titles
Hospital Resident
Biography
Hometown: Kingsville, TX
Medical School: University of California San Francisco
Undergraduate: Harvard College
Professional Interests: Surgical oncology, Cancer research, Health disparities, Health economics, Medical device/diagnostics.
Hobbies: Traveling abroad with my wife Shirley and son Oliver, Ballroom dancing, Running, Basketball
Last Updated on July 24, 2025.
Education & Training
- MD
- University of California San Francisco (2020)
- AB
- Harvard College, Chemical and Physical Biology (2014)
Research
Copy Link
Overview
Medical Research Interests
Artificial Intelligence; Consensus; Cytoreduction Surgical Procedures; Liver; Melanoma, Cutaneous Malignant; Neuroendocrine Tumors; Spatial Analysis; Surgical Oncology; Translational Science, Biomedical
Public Health Interests
Global Health
ORCID
0000-0002-8693-612X
Research at a Glance
Yale Co-Authors
Frequent collaborators of David Su's published research.
Publications Timeline
A big-picture view of David Su's research output by year.
Research Interests
Research topics David Su is interested in exploring.
Kiran Turaga, MD, MPH
Craig Gunderson, MD, SFHM
Harriet Kluger, MD
David Schoenfeld, MD, PhD
Elizabeth Godfrey, MD
Adebowale Adeniran, MD
35Publications
173Citations
Consensus
Cytoreduction Surgical Procedures
Neuroendocrine Tumors
Publications
Featured Publications
SIMVI disentangles intrinsic and spatial-induced cellular states in spatial omics data
Dong M, Su D, Kluger H, Fan R, Kluger Y. SIMVI disentangles intrinsic and spatial-induced cellular states in spatial omics data. Nature Communications 2025, 16: 2990. PMID: 40148341, PMCID: PMC11950362, DOI: 10.1038/s41467-025-58089-7.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsOmics dataSpatial omics dataAnalysis of gene expressionSingle-cell resolutionDownstream analysisCellular statesSpatial interaction modelsGerminal center B cellsGene expressionCommunication machineryOmics technologiesIntercellular interactionsSpatial omics technologiesTumor microenvironmentB cellsSpatial dynamicsHuman tonsilsMacrophage stateSpatial effectsReal-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma
Su D, McNamara M, Kaszycki M, Frey A, Ishizuka J, Costa P, Tran T, Kluger H, Clune J, Weiss S, Olino K. Real-world outcomes with T-VEC in patients with anti-PD-1 resistant in-transit disease from melanoma and Merkel cell carcinoma. Surgical Oncology Insight 2025, 2: 100120. DOI: 10.1016/j.soi.2024.100120.Peer-Reviewed Original ResearchCitationsConceptsMerkel cell carcinomaMerkel cell carcinoma casesT-VECCell carcinomaMedian numberAnti-PD-1 blockadeStage IIIB-IV melanomaAdvanced Merkel cell carcinomaIn-Transit MelanomaIn-transit diseaseICI therapyTalimogene laherparepvecAdvanced melanomaCancer immunotherapyMetastatic sitesPartial responseIn-transitRegional metastasesMedian ageGrade 3Adverse eventsTreatment cyclesDisease progressionMelanomaPatientsMutational Features and Tumor Microenvironment Alterations in High-Grade Appendiceal Cancers Treated With Iterative Hyperthermic Intraperitoneal Chemotherapy
Su D, Dhiman A, Bansal V, Zha Y, Shergill A, Polite B, Alpert L, Turaga K, Eng O. Mutational Features and Tumor Microenvironment Alterations in High-Grade Appendiceal Cancers Treated With Iterative Hyperthermic Intraperitoneal Chemotherapy. JCO Precision Oncology 2024, 8: e2400149. PMID: 39259912, PMCID: PMC11432692, DOI: 10.1200/po.24.00149.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHigh-grade appendiceal adenocarcinomaHyperthermic intraperitoneal chemotherapyProgression-free survivalImmunogenomic profilingAppendiceal cancerIntraperitoneal chemotherapyPeritoneal metastasisHigh-grade appendiceal cancerCD8+ T cellsCytotoxic T cell populationsMutational signaturesAssociated with poor survivalElevated PD-L1Median overall survivalPD-L1 coexpressionPeritoneal tumour depositsT cell populationsTumor microenvironment alterationsNovel treatment approachesWhole-exome sequencingHIPEC treatmentAppendiceal adenocarcinomaOncological outcomesPD-L1Overall survivalMelanocortin-1 Receptor Expression as a Marker of Progression in Melanoma
Su D, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. JCO Precision Oncology 2024, 8: e2300702. PMID: 38662983, PMCID: PMC11513442, DOI: 10.1200/po.23.00702.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMC1R expressionMelanoma progressionAssociated with shorter survivalStages of melanoma progressionCases of benign neviChronic sun exposureMarkers of progressionHuman melanoma tissuesBreslow thicknessMelanocortin-1Metastatic melanomaOverall survivalPrimary melanomaMetastatic tumorsMelanoma cohortReceptor expressionPredictive biomarkersAggressive melanomaPrimary lesionTissue microarrayShorter survivalMale sexQuantitative immunofluorescenceBenign neviClinical trialsDigital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma
Su D, Schoenfeld D, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm D, Khan S, Halaban R, Kluger H, Olino K, Galan A, Clune J. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma. Journal For ImmunoTherapy Of Cancer 2024, 12: e008646. PMID: 38519058, PMCID: PMC10961546, DOI: 10.1136/jitc-2023-008646.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCTLA-4 expression levelsCancer-associated fibroblastsAssociated with worse survivalExpression of immune checkpointsLAG-3 expressionDesmoplastic melanomaLymphoid aggregatesCTLA-4PD-1Immune checkpointsIntratumoral leukocytesLAG-3Tumor compartmentsWorse survivalCD20+B cellsIncreased expression of immune checkpointsProgrammed cell death protein 1Macrophage/monocyte markerSentinel lymph node positivityCell death protein 1Associated with poor prognosisLymph node positivityDense fibrous stromaPotential prognostic significanceCore of tumorsEducational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma
Su D, Kluger H, Olino K. Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma. Annals Of Surgical Oncology 2023, 31: 1865-1879. PMID: 37989956, DOI: 10.1245/s10434-023-14587-w.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricPredicting the broadly neutralizing antibody susceptibility of the HIV reservoir
Yu W, Su D, Torabi J, Fennessey C, Shiakolas A, Lynch R, Chun T, Doria-Rose N, Alter G, Seaman M, Keele B, Lauffenburger D, Julg B. Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. JCI Insight 2019, 4: e130153. PMID: 31484826, PMCID: PMC6777915, DOI: 10.1172/jci.insight.130153.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHIV-1HIV-1-infected individualsHIV-1 sequence diversityAntiretroviral treatment interruptionHIV-infected individualsResistant viral strainsBNAb combinationsBNAb epitopesRebound virusesHIV reservoirCombination regimensTreatment interruptionAntibody therapyControl HIVNeutralization susceptibilityClade virusesBnAbsNeutralizing antibodiesEnv sequencesViral resistanceAntibody susceptibilityNeutralization resistanceHalf-maximal inhibitory concentrationEnvelope protein sequenceViral strainsProtective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys
Julg B, Sok D, Schmidt S, Abbink P, Newman R, Broge T, Linde C, Nkolola J, Le K, Su D, Torabi J, Pack M, Pegu A, Allen T, Mascola J, Burton D, Barouch D. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. Journal Of Virology 2017, 91: 10.1128/jvi.01187-17. PMID: 28768869, PMCID: PMC5625479, DOI: 10.1128/jvi.01187-17.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsImmunodeficiency virusProtective effects inNeutralizing antibodiesSimian-human immunodeficiency virusCirculating HIV strainsResistant to antibody neutralizationRhesus macaquesBroadly Neutralizing AntibodiesPlasma viremiaIncreased levelsSterile protectionHIV strainsBnAbsPGT121Neutralizing activityAntibody neutralizationVirus-antibody combinationsIncomplete neutralizationControl animalsMultiple antibodiesRhesus monkeysPrevent infectionProtective efficacySterilizing activityInput virusPalliative Oncologic Care Curricula for Providers in Resource-Limited and Underserved Communities: a Systematic Review
Xu M, Su D, Deboer R, Garcia M, Tahir P, Anderson W, Kinderman A, Braunstein S, Sherertz T. Palliative Oncologic Care Curricula for Providers in Resource-Limited and Underserved Communities: a Systematic Review. Journal Of Cancer Education 2017, 34: 205-215. PMID: 29264703, DOI: 10.1007/s13187-017-1310-8.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPalliative oncological treatmentSupportive cancer carePalliative careCancer careCare curriculumResource-limited settingsPalliative care education programPrinciples of palliative carePalliative care curriculumAmerican Indian/Alaskan Native communitiesCare education programOncological treatmentProspective cohort studyResource-limited communitiesCancer patientsCumulative IndexSymptom managementWeb of ScienceParticipant satisfactionGrey literatureCareCohort studyOutcome reportingSystematic reviewEducation programsConsensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms
Su D, Brown L, Bansal V, Bakkila B, Concors S, Turaga K, Gunderson C, Bergsland E, Strosberg J, Halfdanarson T, Metz D, Kunstman J, Kunz P, Gangi A, Group P. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms. Cancer 2025, 131: e35871. PMID: 40558053, DOI: 10.1002/cncr.35871.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsManagement of neuroendocrine neoplasmsPeritoneal metastasisNeuroendocrine neoplasmsConsensus guidelinesManagement of peritoneal metastasesClinical management of patientsManagement of PMManagement of patientsComplex clinical challengeLevel of evidenceCytoreductive surgerySurgical resectionSystemic therapyClinical managementClinical challengeLow incidenceModified Delphi techniquePathway blockDisease gradeGrade 1Therapy conceptsHeterogeneous phenotypesFunctional syndromesMultidisciplinary approachMetastasis
Academic Achievements & Community Involvement
Copy Link
Activities
activity Advanced Cancer Therapies Organizing Committee
07/20/2023 - PresentMeeting Planning and ParticipationMemberactivity Society of Asian Academic Surgeons Communications Committee
08/01/2024 - PresentProfessional OrganizationsMemberactivity Society for Surgery of the Alimentary Tract Communications Committee
07/01/2024 - PresentProfessional OrganizationsMember
News
Copy Link
News
- July 10, 2025
AI Outperforms People in Scoring Melanoma Tumor-Infiltrating Immune Cells
- June 27, 2025
Best Practices for Peritoneal Surface Malignancies: A Yale-Led National Expert Consensus
- March 24, 2025
Yale Surgeons to Present at International Surgical Oncology Conference
- November 04, 2022
Albertus Magnus Cancer Research Student Science Day
Get In Touch
Copy Link
Contacts
Email